nivolumab

Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
PD-1 inhibitor benefit possible even after discontinuationPersistent clinical benefit was seen among a small group of patients with metastatic renal cell carcinoma who had to discontinue therapy with the PD-1 inhibitor nivolumab (Opdivo) because of immune-related adverse events, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Antibiotics may negatively impact immunotherapy outcomesAdministration of broad-spectrum antibiotics in patients with metastatic renal cell carcinoma (RCC) undergoing treatment with immune checkpoint inhibitors may have a negative effect on the efficacy of the immunotherapy drugs, according to the results of a recent retrospective analysis.
Urology FDA approvals of 2016Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.
Hodgkin lymphoma: First hematologic cancer cured with immunotherapy?Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.
Uro Pipeline: Data from mUC combination therapy suggests efficacy, safetyOther pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.
Vismodegib study confirms safety, efficacy for BCCThe largest-ever vismodegib study in advanced basal cell carcinoma, the STEVIE study, confirms pivotal study findings in a real-world setting, helping dermatologists to provide a complete palette of skin cancer treatments.
RCC: Two approvals expand options for TKI-refractory patientsFDA approval of second-line therapies could mean an “embarrassment of riches” in this field, according to one expert.
How biomarkers can personalize cancer immunotherapyASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies
Opdivo snags two new cancer approvalsNivolumab (Opdivo, Bristol-Myers Squibb) received two new approvals from FDA to treat two different cancers.